This excerpt taken from the ELN 6-K filed Aug 28, 2009.
Biopharmaceuticals Business Update
Total revenue from our Biopharmaceuticals business increased by 15% to $246.0 million in the first half of 2009 from $213.0 million for the same period of 2008. The increase was driven by strong growth in Tysabri, which more than compensated for reduced sales of Maxipime and Azactam. The decline in sales of Maxipime was primarily due to the impact of generic competition beginning in June 2007 when the first generic product was introduced. The decline in sales of Azactam was principally due to supply shortages. Azactam lost its patent exclusivity in October 2005 and its future sales are expected to be negatively impacted by generic competition. However, no generic form of Azactam has been approved to date. Our sole source for Azactam has indicated they will cease the supply of product to us beyond 2009. We are in discussions with this supplier with respect to its obligations to supply. However, if we are unable to resolve these differences with our supplier or are unable to obtain an alternative source of supply, our sales of Azactam will rapidly decrease.
Total in-market sales of Tysabri were $481.3 million in the first half of 2009, an increase of 34% over the $359.7 million recorded for the same period of 2008, reflecting strong patient demand across global markets. At the end of June 2009, approximately 43,300 patients were on therapy worldwide, including approximately 22,000 commercial patients in the United States and approximately 20,700 commercial patients in rest of world (ROW), representing an increase of 36% over the 31,800 patients who were on therapy at the end of June 2008.
In the first half of 2009, Elan and PharmatrophiX, Inc. (PharmatrophiX), a biotechnology company focused on the development of small molecule ligands for growth factor receptors relevant to neurological disorders, entered into an exclusive collaboration to research, develop and commercialise the neurologic indicators of PharmatrophiXs portfolio of compounds targeting the p75 neurotrophin receptor. The PharmatrohiX portfolio of small molecule compounds, termed p75 ligands, mimic the activity of the neurotrophins, interacting with and potentially protecting neurons that are susceptible to loss in Alzheimers disease. There is also the potential for applications to other neurodegenerative diseases, including Parkinsons disease and MS.
Also in the first half of 2009, Elan initiated a Phase 1 dose escalation safety study of ELND002 in patients with hematologic malignancies. ELND002 is a small molecule injectible inhibitor of alpha 4 beta 1.